Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Therapeutic Equivalency
Conditions
Therapeutic Equivalency
Trial Timeline
Aug 1, 2009 → Sep 1, 2009
NCT ID
NCT01436526About Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) is a phase 1 stage product being developed by Johnson & Johnson for Therapeutic Equivalency. The current trial status is completed. This product is registered under clinical trial identifier NCT01436526. Target conditions include Therapeutic Equivalency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01436526 | Phase 1 | Completed |
Competing Products
11 competing products in Therapeutic Equivalency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| etynodiol diacetate + etynodiol diacetate | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine | Pfizer | Phase 1 | 32 |
| BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111 | Bayer | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |